The Association between the Plasma Sugar and Lipid Profile with the Gene Expression of the Regulatory Protein of mTOR (Raptor) in Patients with Rheumatoid Arthritis

References

• Ansell BJ, Navab M, Hama S, Kamranpour N, Fonarow G, Hough G, Rahmani S, Mottahedeh R, Dave R, Reddy STJC. 2003. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation. 108(22):2751–56.
   PubMed Web of Science ®Google Scholar
• Ansell BJ, Watson KE, Fogelman AM, Navab M, Fonarow GC. 2005. High-density lipoprotein function: recent advances. J Am Coll Cardio. 46(10):1792–98.
   PubMed Web of Science ®Google Scholar
• Armstrong D, McCausland E, Quinn A, Wright G. 2006. Obesity and cardiovascular risk factors in rheumatoid arthritis. Rheumatology. 45(6):782–782.
   PubMedGoogle Scholar
• Azizi F, Rahmani M, Emami H, Mirmiran P, Hajipour R, Madjid M, Ghanbili J, Ghanbarian A, Mehrabi J; Saadat NJS-up. 2002. Cardiovascular risk factors in an Iranian urban population: TLGS (phase 1). Soz Praventivmed. 47:408–26.
   Google Scholar
• Balder J-W, Rimbert A, Zhang X, Viel M, Kanninga R, van Dijk F, Lansberg P, Sinke R, Kuivenhoven JA. 2018. Genetics, lifestyle, and low-density lipoprotein cholesterol in young and apparently healthy women. Circulation. 137(8):820–31.
   PubMed Web of Science ®Google Scholar
• Brennan FM, McInnes IB. 2008. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest. 118(11):3537–45.
   PubMed Web of Science ®Google Scholar
• Burt MG, Roberts GW, Aguilar-Loza NR, Frith P, Stranks SN. 2011. Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD. Clin Endocrinol Metab. 96(6):1789–96.
   Google Scholar
• Charles‐Schoeman C, Yin Lee Y, Shahbazian A, Wang X, Elashoff D, Curtis JR, Navarro‐Millán I, Yang S, Chen L, Cofield S. 2017. Improvement of high‐density lipoprotein function in patients with early rheumatoid arthritis treated with methotrexate monotherapy or combination therapies in a randomized controlled trial. Rheumatology. 69:46–57.
   Web of Science ®Google Scholar
• Chavan VU, Ramavataram D, Patel PA, Rupani MP. 2015. Evaluation of serum magnesium, lipid profile and various biochemical parameters as risk factors of cardiovascular diseases in patients with rheumatoid arthritis. J Clin Diagn Res. 9(4):BC01.
   PubMed Web of Science ®Google Scholar
• Chong ZZ, Maiese K. 2012. Mammalian target of rapamycin signaling in diabetic cardiovascular disease. Cardiovasc Diabetol. 11(1):45.
   PubMedGoogle Scholar
• Crowson CS, Liao KP, Davis III JM, Solomon DH, Matteson EL, Knutson KL, Hlatky MA, Gabriel SE. 2013. Rheumatoid arthritis and cardiovascular disease. Am Heart J. 166(4):e621.
   Web of Science ®Google Scholar
• Desai R, Eddings W, Liao K, Solomon D, Kim SJ. 2014. Disease modifying anti-rheumatic drug use and the risk of incident hyperlipidemia in patients with early rheumatoid arthritis: a retrospective cohort study. Rheumatology. 1911:66.
   Google Scholar
• D-H K, Sabatini D. 2004. Raptor and mTOR: subunits of a nutrient-sensitive complex. In: TOR Target of Rapamycin, edited by Thomas. Berlin, Heidelberg: Springer-Verlag. p 259–70.
   Google Scholar
• Erum U, Ahsan T, Khowaja D. 2017. Lipid abnormalities in patients with rheumatoid arthritis. Pak J Med Sci. 33:227.
   PubMed Web of Science ®Google Scholar
• Escalante A, Haas RW, Del Rincon I. 2005. Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch Intern Med. 165(14):1624–29.
   PubMedGoogle Scholar
• Feng J, Chen Q, Yu F, Wang Z, Chen S, Jin Z, Cai Q, Liu Y, He J. 2016. Body mass index and risk of rheumatoid arthritis: a meta-analysis of observational studies. Medicine. 95:1–8.
   Google Scholar
• Finlay D, Cantrell DA. 2011. Metabolism, migration and memory in cytotoxic T cells. Nat Rev Immunol. 11(2):109.
   PubMed Web of Science ®Google Scholar
• Firestein GS, Budd R, Gabriel SE, McInnes IB, O’Dell JR. 2016. Kelley and Firestein’s textbook of rheumatology E-book: Elsevier health sciences. Philadelphia, PA: Elsevier.
   Google Scholar
• Fox CJ, Hammerman PS, Thompson CB. 2005. Fuel feeds function: energy metabolism and the T-cell response. Nat Rev Immunol. 5:844.
   PubMed Web of Science ®Google Scholar
• Giacomelli R, Cipriani P, Cerinic MM, Fulminis A, Barattelli G, Pingiotti E, Di Franco M, Trotta A, Perricone R, Zazzeroni F. 2002. Combination therapy with cyclosporine and methotrexate in patients with early rheumatoid arthritis soon inhibits TNF production without decreasing TNF mRNA levels. An in vivo and in vitro study. Clin Exp Rheumatol. 20:365–72.
   PubMed Web of Science ®Google Scholar
• Guertin DA, Sabatini DM. 2007. Defining the role of mTOR in cancer. Cancer Cell. 12(1):9–22.
   PubMed Web of Science ®Google Scholar
• Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE, Shaw RJ. 2008. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell. 30(2):214–26.
   PubMed Web of Science ®Google Scholar
• Hahn BH, Grossman J, Chen W, McMahon M. 2007. The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun. 28(2–3):69–75.
   PubMed Web of Science ®Google Scholar
• Hara K, Maruki Y, Long X, Yoshino K-I, Oshiro N, Hidayat S, Tokunaga C, Avruch J, Yonezawa K. 2002. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell. 110(2):177–89.
   PubMed Web of Science ®Google Scholar
• Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N. 2007. Comparison of Disease Activity Score (DAS) 28-erythrocyte sedimentation rate and DAS28-C-reactive protein threshold values. Ann Rheum Dis. 66(3):407–09.
   PubMed Web of Science ®Google Scholar
• Jiang P, Li H, Li X. 2015. Diabetes mellitus risk factors in rheumatoid arthritis: a systematic review and meta-analysis. Clin Exp Rheumatol. 33(1):115–21.
   PubMed Web of Science ®Google Scholar
• Kay J, Upchurch KS. 2012. ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology. 51(suppl 6):vi5–vi9.
   PubMedGoogle Scholar
• Laplante M, Sabatini DM. 2009. mTOR signaling at a glance. J Cell Sci. 122(20):3589–94.
   PubMed Web of Science ®Google Scholar
• Lee PL, Tang Y, Li H, Guertin DA. 2016. Raptor/mTORC1 loss in adipocytes causes progressive lipodystrophy and fatty liver disease. Mol Metab. 5(6):422–32.
   PubMed Web of Science ®Google Scholar
• Libby P. 2006. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr. 83(2):456S–460S.
   PubMed Web of Science ®Google Scholar
• Ma KL, Liu J, Wang CX, Ni J, Zhang Y, Wu Y, Lv LL, Ruan XZ, Liu BC. 2013. Activation of mTOR modulates SREBP-2 to induce foam cell formation through increased retinoblastoma protein phosphorylation. Cardiovasc Res. 100(3):450–60.
   PubMed Web of Science ®Google Scholar
• Ma X, Xu S. 2013. TNF inhibitor therapy for rheumatoid arthritis. Biomedical Reports. 1(2):177–84.
   PubMedGoogle Scholar
• Myasoedova E, Crowson CS, Kremers HM, Fitz-Gibbon PD, Therneau TM, Gabriel SE. 2010. Total cholesterol and LDL levels decrease before rheumatoid arthritis. Ann Rheum Dis. 69(7):1310–14.
   PubMed Web of Science ®Google Scholar
• Myasoedova E, Crowson CS, Kremers HM, Roger VL, Fitz-Gibbon PD, Therneau TM, Gabriel SE. 2011. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis. 70(3):482–87.
   PubMed Web of Science ®Google Scholar
• Myasoedova E, Kremers HM, Fitz-Gibbon P, Crowson C, Therneau T, Gabriel SJ. 2009. Lipid profile improves with the onset of rheumatoid arthritis. Ann Rheum Dis. 68:78.
   Google Scholar
• Navarro‐Millán I, Charles‐Schoeman C, Yang S, Bathon JM, Jr SL B, Chen L, Cofield SS, Dell’Italia LJ, Moreland LW, O’Dell JR. 2013. Changes in lipoproteins associated with methotrexate therapy or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial. Arthritis Rheum. 65(6):1430–38.
   PubMed Web of Science ®Google Scholar
• O’Neill F, Charakida M, Topham E, McLoughlin E, Patel N, Sutill E, Kay CW, D’Aiuto F, Landmesser U, Taylor PC. 2017. Anti-inflammatory treatment improves high-density lipoprotein function in rheumatoid arthritis. Heart. 103(10):766–73.
   PubMed Web of Science ®Google Scholar
• Pereira RMR, de Carvalho JF, Bonfá E. 2009. Metabolic syndrome in rheumatological diseases. Autoimmun Rev. 8(5):415–19.
   PubMed Web of Science ®Google Scholar
• Perl A. 2016. Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases. Nat Rev Rheumatol. 12(3):169.
   PubMed Web of Science ®Google Scholar
• Pfaffl MW. 2001. A new mathematical model for relative quantification in real-time RT–PCR. Nucleic Acids Res. 29(9):e45–e45.
   PubMed Web of Science ®Google Scholar
• Popa C, Netea MG, Van Riel PL, Van Der Meer JW, Stalenhoef AF. 2007. The role of TNF-α in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res. 48(4):751–62.
   PubMed Web of Science ®Google Scholar
• Samimi Z, Kardideh B, Zafari P, Bahrehmand F, Roghani SA, Taghadosi M. 2019. The impaired gene expression of adenosine monophosphate-activated kinase (AMPK), a key metabolic enzyme in leukocytes of newly diagnosed rheumatoid arthritis patients. Mol Biol Rep. 46(6):6353–60.
   PubMed Web of Science ®Google Scholar
• Solomon DH, Kremer J, Curtis JR, Hochberg MC, Reed G, Tsao P, Farkouh ME, Setoguchi S, Greenberg J. 2010. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis. 69(11):1920–25.
   PubMed Web of Science ®Google Scholar
• Staels B, van Tol A, Chan L, Verhoeven G, Auwerx J. 1991. Variable effects of different corticosteroids on plasma lipids, apolipoproteins, and hepatic apolipoprotein mRNA levels in rats. Arterioscler Thromb Vasc Biol. 11(3):760–69.
   Google Scholar
• Symmons DP, Gabriel S. 2011. Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nat Rev Rheumatol. 7(7):399.
   PubMed Web of Science ®Google Scholar
• Toms TE, Panoulas VF, Douglas KM, Griffiths H, Sattar N, Smith JP, Symmons DP, Nightingale P, Metsios GS, Kitas G. 2010. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk? Ann Rheum Dis. 69(4):683–88.
   PubMedGoogle Scholar
• van der Pouw Kraan TC, van Gaalen FA, Kasperkovitz PV, Verbeet NL, Smeets TJ, Kraan MC, Fero M, Tak PP, Huizinga TW, Pieterman E. 2003. Rheumatoid arthritis is a heterogeneous disease: evidence for differences in the activation of the STAT‐1 pathway between rheumatoid tissues. Arthritis Rheum. 48(8):2132–45.
   PubMedGoogle Scholar
• Van Lenten BJ, Reddy ST, Navab M, Fogelman AM. 2006. Understanding changes in high density lipoproteins during the acute phase response. Am Heart Assoc. 26(8):1687–8
   Google Scholar
• Weichhart T, Säemann MD. 2009. The multiple facets of mTOR in immunity. Trends Innunol. 30(5):218–26.
   PubMed Web of Science ®Google Scholar
• Willerson JT, Ridker P. 2004. Inflammation as a cardiovascular risk factor. Circulation. 109:II-2-II-10.
   Web of Science ®Google Scholar